CADILAHC Intraday Analysis...

CADILAHC Share Price

Open 365.00 Change Price %
High 365.65 1 Day -2.75 -0.76
Low 353.45 1 Week 9.35 2.67
Close 359.20 1 Month -11.75 -3.17
Volume 826978 1 Year 57.45 19.04
52 Week High 429.80
52 Week Low 297.40
CADILAHC Important Levels
Resistance 2 370.51
Resistance 1 365.85
Pivot 359.43
Support 1 352.55
Support 2 347.89
NSE INDIA Most Active Stocks
SUZLON 17.35 1.17%
ADANIPOWER 34.35 -11.35%
VISESHINFO 0.25 25.00%
ESL 5.95 -1.65%
ESL 5.95 -1.65%
ESL 5.95 -1.65%
ESL 5.95 -1.65%
AXISBANK 450.75 -6.83%
IDEA 71.50 3.10%
GMRINFRA 12.70 0.40%
More..
NSE INDIA Top Gainers Stocks
ATNINTER 0.25 25.00%
VISESHINFO 0.25 25.00%
ARSHIYA 40.20 20.00%
ICSA 3.35 19.64%
ICSA 3.35 19.64%
GPIL 102.70 18.25%
RUCHISOYA 27.20 13.10%
TARAPUR 6.55 12.93%
ELGIRUBCO 66.45 11.12%
PRAKASHSTL 1.50 11.11%
More..
NSE INDIA Top Losers Stocks
JAIHINDPRO 5.75 -11.54%
ADANIPOWER 34.35 -11.35%
FMNL 45.80 -9.84%
INVENTURE 17.80 -8.72%
PRECOT 69.70 -8.41%
MONNETISPA 25.85 -7.51%
SINTEX 82.70 -7.49%
MRPL 100.60 -7.49%
INDOTHAI 25.20 -7.01%
AXISBANK 450.75 -6.83%
More..

Cadila Healthcare Limited (NSE: CADILAHC)

CADILAHC Technical Analysis 1.5
As on 20th Jan 2017 CADILAHC Share Price closed @ 359.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 355.37 & Sell for SHORT-TERM with Stoploss of 373.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
CADILAHC Target for January
1st Target up-side 400
2nd Target up-side 430.39
3rd Target up-side 460.78
1st Target down-side 313.3
2nd Target down-side 282.91
3rd Target down-side 252.52
CADILAHC Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
CADILAHC Other Details
Segment EQ
Market Capital 40527183872.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.zyduscadila.com
CADILAHC Address
CADILAHC
Zydus Tower
Satellite Cross Roads
Ahmedabad, 380015
India
Phone: 91 79 2686 8100
Fax: 91 79 2686 2365
Interactive Technical Analysis Chart Cadila Healthcare Limited ( CADILAHC NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cadila Healthcare Limited
CADILAHC Business Profile
Cadila Health is in the Pharmaceuticals sector. Cadila Laboratories was founded in 1952 by Ramanbhai Patel(1952–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Shri Indravadan Modi. The company evolved over the next four decades into one of India's established pharmaceutical companies. In 1995 the Patel and Modi families split, with the Modi family's share being moved into a new company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family's holding company. Cadila Healthcare did its IPO on the Bombay Stock Exchange in 2000. Its stock code on the Bombay exchange is 532321. In 2001 the company acquired another Indian pharmaceutical company called German Remedies. On June 25, 2007, the company signed an agreement to acquire 100 per cent stake in Brazil's Quimica e Farmaceutica Nikkho do Brasil Ltda (Nikkho) for around 26 million dollars. In 2010, Cadila Pharmaceuticals received a prestigious Wellcome Trust Award under the new "R&D for Affordable Healthcare in India" initiative. The current market capitalisation stands at Rs 15,310.07 crore.The company has reported a consolidated sales of Rs 1746.79 crore and a Net Profit of Rs 191.57 crore for the quarter ended Sep 2013. The company management includes Pankaj R Patel - Chairman & Managing Director, Sharvil P Patel - Deputy Managing Director, Humayun Dhanrajgir - Director, Mukesh M Patel - Director, Nitin R Desai - Director, Apurva S Diwanji - Director. It is listed on the BSE with a BSE Code of 532321 and the NSE with an NSE Code of CADILAHC. Its Registered office is at "Zydus Tower", Satellite Cross Roads,,Sarkhej Gandhinagar Highway Ahmedabad,Gujarat - 380015.